Philogen announces publication of malignant brain tumor study results in Science Translational Medicine.Press Release
Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation”.
Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here.Always ask the important questions
Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients”
Link to Paper
Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancerNIDLEGY authorisation in nonmelanoma skin cancer
PR Nidlegy Combination Pack Approval
Philogen received combination pack approval for NidlegyTM
Philogen announces Option Exercise by JanssenPR Option Exercise by JANSSEN